Aclaris Therapeutics Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/8/2026)
| Balance Sheet | Total Assets | 160,460,000.00 | ROE | 64.24 % |
| Balance Sheet | Total Equity | 103,082,000.00 | ROA | -40.46 % |
| Cashflow | Capital Expenditures | -111,000.00 | P/FCF | -8.78 |
| Cashflow | Free Cash Flow | -47,224,000.00 | – | – |
| Cashflow | Operating Cash Flow | -47,113,000.00 | P/CF | -8.80 |
| Income | Earnings per Share (diluted) | -0.53 | Div. Yield | – |
| Income | Net Income | -64,923,000.00 | P/E | -6.38 |
| Income | Shares Outstanding | 122,665,000.00 | P/B | 4.02 |
| Income | Total Revenue | 7,826,000.00 | P/S | 52.98 |
Ratios calculated on: 10/14/2026
Company Description
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.aclaristx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more